<DOC>
	<DOCNO>NCT02998879</DOCNO>
	<brief_summary>The main objective study evaluate safety efficacy repeat treatment recombinant human alfa-mannosidase patient alfa-mannosidosis age less 6 year</brief_summary>
	<brief_title>Trial Safety Efficacy Velmanase Alfa Treatment Pediatric Patients With Alpha-Mannosidosis</brief_title>
	<detailed_description>The Primary endpoint study include : - Safety tolerability velmanase alfa per Adverse event ( AEs , include IRR ) , vital sign , laboratory parameter ( hematology , biochemistry urinanalysis ) - Detection anti-velmanase alfa antibody neutralizing/inhibitory antibody The Secondary endpoint include change baseline 24 month follow parameter . Efficacy outcomes : - Serum oligosaccharide - Functional capacity : Peabody Developmental Motor Scale - 2nd edition ( PDMS-2 ) score , Mullen 's Scale Early Learning ( MSEL ) score , Bruininks-Oseretsky Test Of Motor Proficiency-2nd Edition ( BOT-2 ) , applicable age ( 4 year ) upon judgment physician - Endurance : 3-Minute Stair Climb Test ( 3MSCT ) 6-Minute Walk Test ( 6MWT ) pediatric patient 4 year age , applicable accord judgment physician , 2-Minute Walk Test ( 2MWT ) pediatric patient 4 year age , applicable accord judgment physician - Hearing evaluation : Otoacoustic Emissions ( OAE ) testing , Automatic Auditory Brainstem Response ( A-ABR ) audiometry - Immunological profile , applicable upon judgment physician : - CSF biomarkers : Tau protein ( Tau ) , Neurofilament Protein Light ( NFL ) , Glial Fibrillary Acidic Protein ( GFAp ) , Oligosaccharides - Assessment quality life via Questionnaire parent - Assessment mannose-rich oligosaccharide brain tissue , MRI - Pharmacokinetic parameter</detailed_description>
	<mesh_term>Mannosidase Deficiency Diseases</mesh_term>
	<mesh_term>alpha-Mannosidosis</mesh_term>
	<criteria>1 . Patient 's custodial parent ( ) must provide sign ICF prior involvement patient trialrelated activity 2 . The subject 's custodial parent ( ) must ability comply protocol 3 . The subject must confirm diagnosis alphamannosidosis define alphamannosidase activity leukocytes fibroblast &lt; 10 % normal activity ( historical data ) 4 . The subject must age time screen &lt; 6 year . 1 . The subject 's diagnosis confirm alphamannosidase activity &lt; 10 % normal activity 2 . Presence know chromosomal abnormality syndrome affect psychomotor development , alphamannosidosis 3 . History BMT 4 . Presence know clinically significant cardiovascular , hepatic , pulmonary , renal disease medical condition , opinion Investigator , would preclude participation trial 5 . Any medical condition serious intercurrent illness , extenuate circumstance , opinion Investigator , would preclude participation trial 6 . Planned major surgery , opinion Investigator , would preclude participation trial 7 . Participation interventional trial test IMP within last 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>